Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 5Carcinoid Tumor 3Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Neuroendocrine Tumour With Carcinoid Symptoms 1Neuroendocrine Tumors in Lung 1Neoplasm Metastasis 1Gigantism 1Gastrointestinal Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Flushing 1Endocrine Tumors 1Diarrhea 1Acromegaly 1

Interventions

Octreotide 5Everolimus 4pasireotide 3lanreotide 3ganitumab 2gallium Ga 68 dotatate 2cabozantinib 2Nivolumab 2Erlotinib Hydrochloride 2surufatinib 1pertuzumab 1nintedanib 1ibrutinib 1fosbretabulin 1conatumumab 1cixutumumab 1carfilzomib 1arginyllysine 1aflibercept 1Temozolomide 1Sunitinib 1Somatostatin 1Random Allocation 1Ramucirumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Capecitabine 1Bevacizumab 1Axitinib 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Carcinoid Tumor × lanreotide × Clear all
NCT02795858 2025-02-19

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
43 enrolled 11 charts
Endocrine

Carcinoid Tumor

NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡